HAVCR2 and neoplasm: Expression of TIM-3 on CD8+ T cells in the tumor microenvironment is considered a cardinal sign of T cell dysfunction, therefore, TIM-3 blockade could promote anti-tumor immunity by regulating inflammasome activation [47].